青霉素V结构式
|
常用名 | 青霉素V | 英文名 | Penicillin-V |
---|---|---|---|---|
CAS号 | 87-08-1 | 分子量 | 350.389 | |
密度 | 1.5±0.1 g/cm3 | 沸点 | 681.4±55.0 °C at 760 mmHg | |
分子式 | C16H18N2O5S | 熔点 | 120 - 128ºC | |
MSDS | N/A | 闪点 | 365.9±31.5 °C |
青霉素V用途青霉素V(苯氧甲基青霉素)是一种有效的口服抗生素。青霉素V对链球菌、艰难梭菌和金黄色葡萄球菌具有抗菌活性。青霉素V具有研究中耳炎、鼻窦炎、咽炎和扁桃体炎的潜力[1][2][3][4]。 |
中文名 | 青霉素V |
---|---|
英文名 | phenoxymethylpenicillin |
中文别名 | 苯氧甲基青霉素 | 青黴素V |
英文别名 | 更多 |
描述 | 青霉素V(苯氧甲基青霉素)是一种有效的口服抗生素。青霉素V对链球菌、艰难梭菌和金黄色葡萄球菌具有抗菌活性。青霉素V具有研究中耳炎、鼻窦炎、咽炎和扁桃体炎的潜力[1][2][3][4]。 |
---|---|
相关类别 | |
体外研究 | 青霉素V(0.002-8.0mg/L)抑制链球菌的生长,最低抑制浓度(MIC)为0.004-0.008mg/L[2]。青霉素V(0.002-8.0 mg/L)对艰难梭菌具有抗菌活性,MIC50值为4.0 mg/L,MIC90值为8.0 g/L[3]。青霉素V(0.004-0.063 mg/L;18 h)抑制金黄色葡萄球菌的生长,MIC值为0.016 mg/L[4]。 |
体内研究 | 青霉素V(0.063-0.25mg/kg;s.c.)抑制小鼠大腿肌肉中金黄色葡萄球菌的生长[4]。青霉素V(2 mg/kg;s.c.)的血浆半衰期(61 min)和平均AUC(0.47 mg/L·h)[4]。青霉素V(100mg/kg;每天一次,持续5天)可避免大鼠急性化脓性中耳炎(AOM)的暴发性感染[5]。动物模型:无特异性病原体(SPF)雄性瑞士小鼠(20-25 g)接种金黄色葡萄球菌[4]剂量:0.063、0.13、0.25 mg/kg给药:S.c.结果:与对照组(3.5×107计数/mL)相比,0.25 g/kg剂量下的CFU数量(1.34×107计数/mL)减少。 |
参考文献 |
密度 | 1.5±0.1 g/cm3 |
---|---|
沸点 | 681.4±55.0 °C at 760 mmHg |
熔点 | 120 - 128ºC |
分子式 | C16H18N2O5S |
分子量 | 350.389 |
闪点 | 365.9±31.5 °C |
精确质量 | 350.093628 |
PSA | 121.24000 |
LogP | 1.88 |
外观性状 | 白色至灰白色结晶粉末 |
蒸汽压 | 0.0±2.2 mmHg at 25°C |
折射率 | 1.651 |
储存条件 | −20°C |
稳定性 | Stable. Combustible. Incompatible with strong oxidizing agents. |
水溶解性 | Very slightly soluble in water, soluble in ethanol (96 per cent). |
青霉素V上游产品 8 | |
---|---|
青霉素V下游产品 3 | |
海关编码 | 3003101300 |
---|
Fast targeted analysis of 132 acidic and neutral drugs and poisons in whole blood using LC-MS/MS.
Forensic Sci. Int. 243 , 35-43, (2014) The aim of this study was to develop an LC-MS/MS based screening technique that covers a broad range of acidic and neutral drugs and poisons by combining a small sample volume and efficient extraction... |
|
Molecularly imprinted polymer nanocarriers for sustained release of erythromycin.
Pharm. Res. 32(2) , 375-88, (2015) To develop and evaluate molecularly imprinted nanocarriers for sustained release of erythromycin in physiological buffer media.Erythromycin-imprinted poly(methacrylic acid-co-trimethylolpropane trimet... |
|
Follow-up study of implants with turned or oxidized surfaces placed after sinus augmentation.
Int. J. Oral Maxillofac. Implants 29(6) , 1380-7, (2014) To compare long-term survival and clinical outcomes of endosseous implants with different surface characteristics in patients with sinus elevation procedures, autologous bone grafting, and delayed imp... |
penicillin-V |
Oracillin |
Pen-vee-oral |
Fenospen |
(2S,5R,6R)-3,3-Dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
Penicillin phenoxymethyl |
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
PenicillinV |
Phenocillin |
Beromycin |
(2S,5R,6R)-3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid |
Phenopenicillin |
Acipen-V |
Phenomycilline |
Phenospen |
V-Cillin |
[2S-(2a,5a,6b)]-3,3-Dimethyl-7-oxo-6-[(phenoxy acetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic Acid |
Orocillin |
penicillin V |
6-phenoxyacetamidopenicillanic acid |
dowpen v-k |
4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(2-phenoxyacetyl)amino]-, (2S,5R,6R)- |
4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-7-oxo-6-[(phenoxyacetyl)amino]-, (2S,5R,6R)- |
penicillin VK |
Phenoxymethylpenicillin |